Brian Shafer, MD
Cornea and External Diseases Specialist · Plymouth Meeting, PANPI 1982054433
Payments from drug & device makers
Across 457 payments — averaging $2090.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$420K
- Rayner Intraocular Lenses Limited$212K
- Alcon$212K
- Glaukos Corporation$50K
- Alcon Research LLC$46K
- AbbVie$8K
- plus $7K from 20 others
Across 5 payments — averaging $212,462 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$1.1M
- Rayner Intraocular Lenses Limited$2K
What the payments were for
- Consulting fees$629,27086%
- Speaking & faculty fees$68,2919%
- Travel & lodging$25,5443%
- Food & beverage$12,8302%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 16 | $419,821 |
| Rayner Intraocular Lenses Limited | 12 | $212,470 |
| Alcon | 245 | $212,261 |
| Glaukos Corporation | 56 | $49,803 |
| Alcon Research LLC | 26 | $46,392 |
| AbbVie(2 entities) | 46 | $7,954 |
| Dompe US, Inc. | 5 | $1,895 |
| Bausch & Lomb Americas Inc. | 3 | $1,444 |
| Carl Zeiss Meditec, Inc. | 3 | $1,066 |
| Carl Zeiss Meditec USA, Inc. | 4 | $877 |
| Biotissue Holdings Inc. | 7 | $271 |
| Sight Sciences, Inc. | 5 | $226 |
| Oyster Point Pharma, Inc. | 4 | $186 |
| Tarsus Pharmaceuticals, Inc. | 5 | $122 |
| Quidel Corporation | 1 | $105 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $86 |
| Harrow Eye, LLC | 4 | $80 |
| Ocular Therapeutix, Inc. | 3 | $74 |
| NEW World Medical,inc. | 4 | $56 |
| Thea Pharma Inc. | 1 | $38 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Omeros Corporation | 1 | $15 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT INJECTOR HANDPIECE$419,621
- RXSIGHT CONTACT LENS$419,621
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$419,621
- RXSIGHT INJECTOR CARTRIDGE$419,621
- LIGHT ADJUSTABLE LENS (LAL)$419,490
- Clareon$144,178
- AcrySof IQ PanOptix UV IOL$83,889
- AcrySof IQ VIVITY$52,590
- Hydrus Microstent$18,176
- iDose$18,064
- OMIDRIA$15,607
- Travoprost Intraocular Implant - iDose$10,500
- DURYSTA$4,313
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$4,050
- AcrySof Toric Aspheric UV Absorbing IOL$3,660
- Voyager DSLT$3,500
- Centurion$2,940
- iStent Trabecular Micro-Bypass Stent System$2,800
- iStent Trabecular Micro-Bypass System Model iS3$2,609
- AcrySof IQ PanOptix$2,412
How this compares
Too few cornea and external diseases specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 15 | $7,964 |
| RestasisCyclosporine | 12 | $7,795 |
| Prednisolone Acetate | 172 | $7,544 |
| Ketorolac Tromethamine | 47 | $1,222 |
| MoxifloxacinMoxifloxacin Hcl | 75 | $1,198 |
| Latanoprost | 79 | $862 |
| ValacyclovirValacyclovir Hcl | 14 | $672 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $312 |
| Brimonidine Tartrate | 14 | $285 |
| Timolol Maleate | 19 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $7,954 | $15,75927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Plymouth Meeting
- Giacomina Massaro-GiordanoPhiladelphia$912K
- Vatinee BunyaPhiladelphia$293K
- Stuart CarterAllentown$4K
- Hamza PashaCranberry Township$3K
- Kevin ShahWyomissing$3K
- Stephen OrlinPhiladelphia$3K
- Mira AminNorth Wales$2K
- Sabrina MukhtarPittsburgh$2K
- John FiletaLancaster$2K
- Samantha MarekWest Chester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.